Indiana Patent of the Month – March 2024
Neurodon Corporation was founded to explore a new way to approach disease: cellular stress and calcium imbalance in the cell. With this goal in mind, the company has worked to develop therapeutics inspired by this approach. Some of these therapeutics are now under preclinical development to address diabetes, Alzheimer’s and more.
Recently, the company was granted a patent for a treatment using quinolones in the treatment of diabetes and neurological disorders. This method presents a promising avenue for addressing the intricate challenges posed by conditions such as type 1 and type 2 diabetes, Alzheimer’s disease, Parkinson’s disease, and more.
The core of this innovation lies in the modulation of the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), a pivotal regulator of cellular homeostasis. By targeting SERCA activity, Neurodon LLC’s compounds offer a multifaceted approach to combating the detrimental effects of endoplasmic reticulum (ER) stress, a common denominator in various diseases.
The significance of this invention stems from its potential to address the root causes of ER stress-related disorders. The endoplasmic reticulum plays a crucial role in maintaining cellular functions, and disturbances in its homeostasis can lead to a cascade of detrimental effects, including protein misfolding, inflammation, and cell death. Neurodon’s compounds offer a means to restore ER function and alleviate the burden of disease on affected individuals.
Moreover, the versatility of these compounds extends beyond diabetes to encompass a spectrum of neurological disorders. From Alzheimer’s to Parkinson’s disease, the ability to modulate SERCA activity presents a promising therapeutic strategy with far-reaching implications for patient care.
The efficacy of Neurodon’s compounds is underscored by compelling preclinical data, demonstrating their ability to reduce blood glucose levels, inhibit amyloid plaque formation, and improve memory and coordination in animal models.
Neurodon’s invention targets the fundamental mechanisms underlying ER stress-related disorders. Their compounds hold promise for revolutionizing the treatment landscape for diabetes and neurological conditions.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
